Evaluating an incobotulinumtoxinA and Cohesive Polydensified Matrix® hyaluronic acid filler combination to treat moderate-to-severe periorbital and perioral rhytids.

Abstract

To evaluate the effectiveness of treating mimetic facial lines with an incobotulinumtoxinA (INCO) and Cohesive Polydensified Matrix® hyaluronic acid (CPM-HA) combination. Subjects with moderate-to-severe lateral periorbital lines (LPL) and perioral lines at rest according to Merz Aesthetics Scales™ received 10U of INCO/eye and up to 10U to the perioral area. This was followed by intradermal injection of 1-3cc CPM-HA to the same lines. Primary outcomes were physician- and subject-rated improvement at 1month using the Global Aesthetic Improvement Scale (GAIS) and changes in line severity using the Merz Aesthetics Scales™ . The study included 10 women aged 42-74years with moderate-to-severe LPL and perioral lines at baseline. At 1month, treating physician GAIS scores indicated 45.0% of subjects were very much improved and 52.5% much improved; 75% remained at least improved at 6months. Subject GAIS results indicated 7 women rated themselves as very much improved and 3 as much improved. For LPL, improvements of ≥1-point on the Merz Aesthetics Scales™ compared with baseline were seen at 1, 3, and 6months in 86.8%, 74.3%, and 65.8% of subjects, respectively. For perioral lines, improvements of ≥1-point were observed for 89.2%, 86.5%, and 73.0% at 1, 3, and 6months, respectively. No treatment-related adverse events were observed. Combined INCO/CPM-HA filler in individuals with moderate-to-severe LPL and perioral lines was effective at improving overall appearance and reducing line severity in two highly mobile facial areas that are the first to show lines of aging.